Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.

MLA

Oyanagi, Jun, et al. “Predictive Value of Serum Protein Levels in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab.” Lung Cancer (Amsterdam, Netherlands), vol. 132, June 2019, pp. 107–13. EBSCOhost, https://doi.org/10.1016/j.lungcan.2019.03.020.

APA

Oyanagi, J., Koh, Y., Sato, K., Mori, K., Teraoka, S., Akamatsu, H., Kanai, K., Hayata, A., Tokudome, N., Akamatsu, K., Nakanishi, M., Ueda, H., & Yamamoto, N. (2019). Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab. Lung Cancer (Amsterdam, Netherlands), 132, 107–113. https://doi.org/10.1016/j.lungcan.2019.03.020

Chicago

Oyanagi, Jun, Yasuhiro Koh, Koichi Sato, Keita Mori, Shunsuke Teraoka, Hiroaki Akamatsu, Kuninobu Kanai, et al. 2019. “Predictive Value of Serum Protein Levels in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab.” Lung Cancer (Amsterdam, Netherlands) 132 (June): 107–13. doi:10.1016/j.lungcan.2019.03.020.